ABBV - AbbVie Inc. Latest News | Finranks

14.10.2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.

14.10.2026

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

14.10.2026

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.

13.10.2026

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira. Novo Nordisk maintains a dominant lead in the rapidly expanding metabolic health market through its blockbuster obesity treatments.

13.10.2026

5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income

Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking names on the list look stingy by comparison.

13.10.2026

Netflix, DocuSign And A Health Care Stock On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked Netflix, Inc. (NASDAQ:NFLX).

12.10.2026

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie continues to diversify its portfolio through the successful expansion of newer therapies like Skyrizi and Rinvoq. Eli Lilly and has seen explosive growth driven by its dominant presence in the massive cardiometabolic treatment market.

Videos

24.08.2026

Positive

Emily Field: Large pharma companies are going to continue looking at biotech

14.08.2026

Positive

Expert explains why healthcare is a top-performing sector

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
ABBV	Wolfe Research	Outperform	undefined >> $300	August 13th 2026
ABBV	Erste Group	Buy	undefined >> undefined	August 5th 2026

Press releases

11.10.2026

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure In real-world studies, patients with advanced Crohn's disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie's pursuit to address the complexities of inflammatory bowel disease care NORTH CHICAGO, Ill., Oct. 11, 2026 /PRNewswire/ -- AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee, Oct. 9-14.

AbbVie Inc. (ABBV)

Get all premium features to the best stock analysis tool

Finranks

Contact us

Follow us

AbbVie Inc. (ABBV)

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income

Netflix, DocuSign And A Health Care Stock On CNBC's ‘Final Trades'